Novavax’s performance

As per its 2Q15 earnings report, Novavax’s (NVAX) total revenue has gone up by 41.70% from 1Q15 driven by successful clinical tests of new drugs. Novavax has gotten positive results from clinical trials on drugs to treat Ebola and seasonal influenza.

Successful Clinical Tests Give Novavax a Boost in 2Q15

Gross margins rise from successful clinical tests

The gross margin for Novavax was 80.80%. Gross margins for its competitors Vical (VICL), Biota Pharmaceuticals (BOTA), Merck & Co. (MRK), Sinovac Biotech, and AstraZeneca (AZN) were 43.03%, 94.92%, 62.71%, 73.74%, and 84%, respectively. This shows that Novavax has performed well as compared to its competitors. The PowerShares Dynamic Pharmaceuticals ETF (PJP) has 5.15% of its holding in Novavax.

About Novavax

Novavax is a clinical-stage vaccine company. Its main focus point is on discovery, maturation, and commercialization of recombinant nanoparticle and adjuvants. The company targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus, seasonal influenza, pandemic flu, and ebola virus. The company’s recombinant nanoparticles and Matrix-M adjuvant technology aim to improve human health and safety.

Latest articles

MedMen (MMNFF) (MMEN) closed 1.9% higher on Thursday. The company launched a 2020 ballot initiative called “Make it Legal Florida."

On Thursday, James Anderson of Baillie Gifford did an interview with Manager Magazin. Anderson discussed why he thinks Tesla could work without Musk.

HEXO reported its third-quarter earnings on June 12. The company reported revenues of $13.0 million, which fell short of analysts’ estimate.

The Hot Chips 31 Symposium started this week. Artificial intelligence was the hot topic among participants Intel, NVIDIA, and Advanced Micro Devices.

Today, Slack (WORK) opened 4.5% higher after MKM Partners analyst Rohit Kulkarni gave Slack stock a "buy" rating with a target price of $40.

Today, Aphria announced a deal with ParcelPal to deliver medical cannabis to patients. Also, Cole Cacciavillani's son has won a cannabis store license.